SUPERSTRING CAPITAL MANAGEMENT LP Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001931118
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2024 · 27 positions · Total reported value $99.11M · Top-10 concentration 77.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 65.1% · 8 new · 9 cut · 11 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +26.6% · vs SPY +11.8% · Prev Value $139.97M — last quarter positions weighted by this quarter price moves · ranking
In its Q3 2024 13F filing, SUPERSTRING CAPITAL MANAGEMENT LP disclosed 27 equity positions with a combined reported value of $99.11M. The filing implies a focused portfolio: its ten largest positions account for 77.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2024 were CYTK ($11.39M), TERN ($11.25M), GPCR ($9.97M). By sector, the heaviest allocations are Health Care 83.2%, Other 16.8%. Versus the prior quarter, allocation shifted toward Health Care (+8.6pp) and away from Other (-8.2pp).
Versus the prior quarter, SUPERSTRING CAPITAL MANAGEMENT LP opened 8 new positions, trimmed 9 and fully exited 11, a turnover rate of 65.1% of positions. The portfolio's overlap with the prior quarter was 40% of names.
The largest new positions opened in Q3 2024 were GPCR ($9.97M), ORIC ($9.73M), TIL ($7.24M).
Of the 11 positions fully exited versus the prior quarter, the largest were KROS ($3.39M), ACLX ($3.26M), ARWR ($2.89M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2024)
Fully Exited (vs previous quarter)
- KROS KEROS THERAPEUTICS INC · prev qtr: $3.39M
- ACLX ARCELLX INC · prev qtr: $3.26M
- ARWR ARROWHEAD PHARMACEUTICALS IN · prev qtr: $2.89M
- ONC BEONE MEDICINES LTD · prev qtr: $1.78M · history
- PYXS PYXIS ONCOLOGY INC · prev qtr: $1.60M
- APGE APOGEE THERAPEUTICS INC · prev qtr: $1.45M
- CTMX CYTOMX THERAPEUTICS INC. · prev qtr: $1.40M
- NAMS NEWAMSTERDAM PHARMA COMPANY · prev qtr: $1.23M
Insider Transactions (Form 4)
Latest SUPERSTRING CAPITAL MANAGEMENT LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Superstring Capital Management, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 32 positions worth $158.38M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-118766 (status: Approved), registered 2020-05-20
- Regulatory AUM (Form ADV): $339.50M as of 2026-03-30
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 1 hedge funds
- Website: superstringcap.com
Portfolio Structure
- 32 positions · $158.38M reported value (Q2 2026)
- Top 10 holdings = 63.8% of reported value
- Largest position: COGT (COGENT BIOSCIENCES INC) at 8.4%
- Average position size: $4.95M
Sector Tilt
- Health Care 99.8%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 8 new, 12 added, 9 reduced, 11 exited
- 3 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
215.80K | $11.39M | 11.50% | Add | |
| 2 |
|
1.35M | $11.25M | 11.35% | Add | |
| 3 |
|
227.05K | $9.97M | 10.05% | New | |
| 4 |
|
949.52K | $9.73M | 9.82% | New | |
| 5 |
|
107.55K | $7.24M | 7.30% | New | |
| 6 |
|
392.71K | $6.14M | 6.19% | Add | |
| 7 |
|
226.68K | $5.77M | 5.82% | Add | |
| 8 |
|
1.47M | $5.13M | 5.18% | Add | |
| 9 |
|
337.35K | $5.13M | 5.18% | New | |
| 10 |
|
599.05K | $4.61M | 4.65% | Add | |
| 11 |
|
595.20K | $4.40M | 4.44% | Reduce | |
| 12 |
|
740.29K | $3.35M | 3.38% | Reduce | |
| 13 |
|
60.52K | $2.95M | 2.98% | Reduce | |
| 14 |
|
100.00K | $2.41M | 2.44% | Reduce | |
| 15 |
|
111.61K | $1.89M | 1.91% | New | |
| 16 |
|
478.12K | $1.34M | 1.35% | Reduce | |
| 17 |
|
37.29K | $1.10M | 1.11% | Reduce | |
| 18 |
|
200.00K | $848.00K | 0.86% | Hold | |
| 19 |
|
83.55K | $843.89K | 0.85% | Reduce | |
| 20 |
|
29.10K | $748.26K | 0.76% | Reduce | |
| 21 |
|
156.63K | $635.90K | 0.64% | Hold | |
| 22 |
|
131.79K | $622.07K | 0.63% | Reduce | |
| 23 |
|
25.40K | $524.02K | 0.53% | Reduce | |
| 24 |
|
12.45K | $354.86K | 0.36% | New | |
| 25 |
|
20.84K | $348.86K | 0.35% | New | |
| 26 |
|
307.92K | $212.16K | 0.21% | Hold | |
| 27 |
|
33.82K | $172.16K | 0.17% | New | |
FAQ
What did SUPERSTRING CAPITAL MANAGEMENT LP buy in 2024-Q3?
In its 2024-Q3 13F filing, SUPERSTRING CAPITAL MANAGEMENT LP reported 27 equity positions worth $99.11M in aggregate; its largest disclosed positions were CYTK ($11.39M), TERN ($11.25M), GPCR ($9.97M).
How large is SUPERSTRING CAPITAL MANAGEMENT LP's portfolio?
SUPERSTRING CAPITAL MANAGEMENT LP reported $99.11M of long equity holdings across 27 positions as of 2024-Q3. Top-10 holdings account for 77.0% of reported value.
What is SUPERSTRING CAPITAL MANAGEMENT LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.